Robust Target Identification for Drug Discovery
نویسندگان
چکیده
منابع مشابه
Mechanism-based target identification and drug discovery in cancer research.
Cancer as a disease in the human population is becoming a larger health problem, and the medicines used as treatments have clear limitations. In the past 20 years, there has been a tremendous increase in our knowledge of the molecular mechanisms and pathophysiology of human cancer. Many of these mechanisms have been exploited as new targets for drug development in the hope that they will have g...
متن کاملChemical proteomics applied to target identification and drug discovery.
Introduction In the past decade, DNA sequencing of multiple organisms has provided us with our first look at complete lists of protein products expressed from a whole genome. The field of proteomics is now challenged with the task of elucidating the cellular functions of these proteins in both normal and pathological processes (1–3). Several proteomic techniques, such as 2-dimensional gel-elect...
متن کاملComputational approaches in target identification and drug discovery
In the big data era, voluminous datasets are routinely acquired, stored and analyzed with the aim to inform biomedical discoveries and validate hypotheses. No doubt, data volume and diversity have dramatically increased by the advent of new technologies and open data initiatives. Big data are used across the whole drug discovery pipeline from target identification and mechanism of action to ide...
متن کاملTarget assessment for antiparasitic drug discovery.
Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maxi...
متن کاملDrug–Target Kinetics in Drug Discovery
The development of therapies for the treatment of neurological cancer faces a number of major challenges including the synthesis of small molecule agents that can penetrate the blood-brain barrier (BBB). Given the likelihood that in many cases drug exposure will be lower in the CNS than in systemic circulation, it follows that strategies should be employed that can sustain target engagement at ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: IFAC-PapersOnLine
سال: 2016
ISSN: 2405-8963
DOI: 10.1016/j.ifacol.2016.07.290